Drug Details

General Information of the Drug (ID: DR8004)
Name
Sorbitan trioleate
Synonyms
Sorbitan, tri-(9Z)-9-octadecenoate; UNII-QE6F49RPJ1; QE6F49RPJ1; Glycomul TO; Liposorb TO; Protachem STO; Sorbitani trioleas; Sorbitan, trioleate; Crill 5; Trioleate de sorbitan; Emasol 430; Rheodol SP 030; Trioleato de sorbitano; Emsorb 2503; Ionet S 85; Nissan nonion OP 85; Anhydrosorbitol trioleate; Nissan nonion OP 85R; Anhydro-D-glucitol trioleate; Sorbitan, tri-9-octadecenoate; OP 85R; CHEMBL3989778; Sorbitani trioleas [INN-Latin]; TE 33; EINECS 247-569-3; Trioleate de sorbitan [INN-French]; Trioleato de sorbitano [INN-Spanish]; Sorbitan trioleate [USAN:INN:BAN:NF]; Sorbitan, tris(9-octadecenoate), (Z)-; AI3-03902; EC 247-569-3; Sorbitan, esters, tri-9-octadecenoate, (Z,Z,Z)-; Sorbitan, tri-9-octadecenoate, (Z,Z,Z)- (9CI); Q27287216; UNII-MDL271E3GR component PRXRUNOAOLTIEF-ADSICKODSA-N; Sorbitan trioleate. (Compound usually contains also associated fatty acids.); [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate
    Click to Show/Hide
Molecular Type
Small molecule
Disease Brain cancer [ICD-11: 2A00] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C60H108O8
PubChem CID
9920343
Canonical SMILES
CCCCCCCCC=CCCCCCCCC(=O)OCC(C1C(C(CO1)O)OC(=O)CCCCCCCC=CCCCCCCCC)OC(=O)CCCCCCCC=CCCCCCCCC
InChI
1S/C60H108O8/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-56(62)65-53-55(67-57(63)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2)60-59(54(61)52-66-60)68-58(64)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3/h25-30,54-55,59-61H,4-24,31-53H2,1-3H3/b28-25-,29-26-,30-27-/t54-,55+,59+,60+/m0/s1
InChIKey
PRXRUNOAOLTIEF-ADSICKODSA-N
CAS Number
CAS 26266-58-0
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Palmitic acid      Myrmecophilus sp. palM     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Staphylococcus aureus Microorganism model Staphylococcus aureus
                    Experimental
                    Result(s)		 Combinatorial therapy with a low concentration of oxacillin controlled different laboratory and highly diversified clinical MRSA strains.
References
Reference 1 The Aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme. Oncology. 2013;84(6):326-35.
Reference 2 Combination Therapy Using Low-Concentration Oxacillin with Palmitic Acid and Span85 to Control Clinical Methicillin-Resistant Staphylococcus aureus. Antibiotics (Basel). 2020 Oct 8;9(10):682.
 Download Picture         KEGG Link